Track the Marrone BIO Innovations INC share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on US US, under the authority of SEC (Form 4). Operating in the Food & Agriculture sector, Marrone BIO Innovations INC has published 18 reports. The latest transaction was filed on 15 July 2022 (U). Among the most active insiders: Marrone Pamela G. All data is openly available.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
18 of 18 declarations
Marrone Bio Innovations Inc. was a United States-based agricultural biologicals company focused on crop protection, plant health, and, to a lesser extent, crop nutrition. Before its merger, the company was listed on the NASDAQ in the United States and was headquartered in Davis, California. Its business model centered on providing growers with biological or naturally derived alternatives to conventional chemical inputs, a positioning aligned with the long-term industry shift toward sustainability, residue reduction, and integrated pest management. The company was founded in 2006 by Pamela Marrone, a well-known entrepreneur in agricultural biotechnology with a long track record in the crop protection sector. Marrone Bio Innovations built its franchise around proprietary discovery and screening platforms designed to isolate microorganisms and plant extracts with agronomic benefits. Over time, it developed a portfolio of branded products that included Regalia, Grandevo, Venerate, Majestene, Zelto, Stargus, Haven, Jet-Ag, and Jet-Oxide. These products addressed a broad set of crop issues, including fungal diseases, insects, mites, nematodes, and specialized plant health applications across row crops, specialty crops, turf, ornamentals, and other use cases. From a competitive standpoint, Marrone Bio Innovations operated in a niche but structurally attractive segment of the crop inputs market. Its differentiation came from biological innovation, intellectual property, regulatory expertise, and relationships with distributors rather than from scale alone. The company competed against both traditional agrochemical players expanding into biologicals and a growing set of specialist biopesticide developers. Its product breadth and pipeline helped it participate in a market that was becoming increasingly receptive to lower-toxicity, environmentally oriented solutions. Geographically, the business was anchored in North America, with research and development activity associated with Davis, California, and manufacturing supported through internal and third-party arrangements. The company also sold products internationally through distributors and commercial partners, giving it exposure beyond the U.S. market. A notable milestone was the acquisition of Pro Farm, which broadened the company’s biological crop input platform with additional products and capabilities. The most important recent corporate event was the merger completed in July 2022 with Bioceres Crop Solutions. As a result, Marrone Bio Innovations was folded into the combined group and no longer operated as an independent standalone public company. For investors, the Marrone Bio Innovations name is therefore best understood as a legacy NASDAQ-listed U.S. agricultural biologicals platform that contributed technology, products, and commercial know-how to a broader sustainable agriculture group.